跳至主要内容
临床试验/NCT05182645
NCT05182645已完成不适用

MBMCrohn: Die Wirkung Eines Stressreduktion- Und Lebensstilmodifikations-programms Auf Die Lebensqualität Von Patienten Mit Morbus Crohn- Eine Machbarkeitsstudie

Jost Langhorst2 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2020年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
42
试验地点
2
主要终点
Recruitment success

研究概览

简要总结

Patients with crohn's disease often suffer significant limitations to their quality of life, which are also conditioned by particular stress and psychosocial accompanying symptoms of the disease. A multimodal program for stress-reduction and lifestyle-modification has been shown to be effective in promoting the quality of life in patients with uncreative colitis. The study will examine the promotion of the quality of life of patients with crohn's disease and the positive Influence on stress, psychological symptoms and physiological parameters.

详细描述

40 patients with ulcerative colitis will be randomized in an Intervention group and a control group for 10 weeks. The primary outcome is the feasibility of the study, the intervention and the examinations. The Secondary outcomes are disease-specific quality of life, disease-activity, stress, psychological symptoms, inflammatory parameters, disease activity parameters, bowel parameter and the microbiome. As qualitative parameters, the influence of the disease on everyday life and the experience/ impact/ implementability of the programme will be investigated. Lastly, undesirable events will be recorded.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age between 18 and 75 years
  • Presence of a confirmed diagnosis of Crohn's disease
  • In remission (not longer than 12 months, or mild to moderate clinical activity (HBI < 16)
  • Medication that has been stable for at least 3 months, regardless of whether glucocorticoids, immunosuppressive drugs, azathioprine, or other drug treatments according to MBMCrohn - Version 1.0 from 06.12.2019 Page 7 Guideline
  • Signed declaration of consent

排除标准

  • infectious or refractory Crohn's disease with severe course
  • Complete colectomy
  • Severe psychological illness (e.g. depression requiring treatment, addiction, schizophrenia)
  • Severe comorbid somatic disease (e.g. diabetes mellitus, oncological disease)
  • Pregnancy
  • Participation in stress reduction programmes or clinical studies on psychological interventions

结局指标

主要结局

Recruitment success

时间窗: week 48

Proportion of people responding to appeals for studies

Attendance

时间窗: week 48

Proportion of people which actually attend the study

Willingness to participate

时间窗: week 48

Proportion of people which actually agreed in relation to the proportion of people which responded to the appeal.

Loss of participants over the study period

时间窗: week 48

Proportion of people who quit during the study

次要结局

  • (PMN)-elastase(week 48)
  • creatinin(week 48)
  • intestinal microbiome(week 36)
  • Intestinal permeability(week 0)
  • sex (questionnaire)(week 0)
  • Generic quality of life by SF-36(week 0)
  • Generic quality of life by SF 36(week 12)
  • Disease activity 2 by BHI(week 0)
  • Coping strategies by COPE(week 48)
  • lymphocyte (T-cell) profiling(week 36)
  • alpha-1- antitrypsin(week 12)
  • Flourishing by FS-D(week 48)
  • Core Self-Evaluation by CSES(week 48)
  • qualitatives Interview(week 36)
  • professional career (questionnaire)(week 0)
  • CRP (C-reactive protein)(week 48)
  • heart rate(week 12)
  • Adverse events(week 48)
  • Generic quality of life by SF36(week 48)
  • Anxiety and depression by HADS(week 48)
  • Perceived stress by PSS(week 48)
  • calprotectin(week 48)
  • Human beta-defensin-2 (hBD-2)(week 48)
  • prolactin levels(week 12)
  • School career (questionnaire)(week 0)
  • occupation (questionnaire)(week 0)
  • Disease-specific quality of life by IBD-Q(week 48)
  • lactoferrin(week 48)
  • cortisol(week 12)
  • ACTH(week 12)
  • alpha-1-antitrypsin(week 48)
  • Disease activity by HBI(week 48)
  • BSG (blood cell sedimentation rate)(week 48)
  • zonulin(week 48)
  • glucocorticoid and β-adrenergic regulation of IL-8 and IL-10(week 12)
  • TNF-α production by peripheral blood cells(week 12)
  • blood pressure systolic and diastolic(week 12)
  • STAI-S(week 12)
  • marital status (questionnaire)(week 0)
  • age (questionnaire)(week 0)
  • weight(week 0)
  • body height(week 0)
  • job (questionnaire)(week 0)

研究者

发起方
Jost Langhorst
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jost Langhorst

Clinical Professor

Universität Duisburg-Essen

研究点 (2)

Loading locations...

相似试验